Market Place
Sourcing Support
Vedanta Biosciences To Present VE303 Benefits At IDWeek 2024
16 Oct 2024 //
BUSINESSWIRE
Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
23 Jul 2024 //
BUSINESSWIRE
Vedanta Biosciences Expands Leadership Team
23 Jul 2024 //
BUSINESSWIRE
Vedanta Enrolls First Phase 3 VE303 C. Diff Prevention Patient
21 May 2024 //
BUSINESSWIRE
PureTech`s Vedanta Enrolls First Phase 3 VE303 C. Diff Prevention Patient
21 May 2024 //
BUSINESSWIRE
Vedanta Biosciences to Present at Upcoming Investor Conferences
29 Apr 2024 //
BUSINESSWIRE
Vedanta lays off CMC staffers; Kincell buys Imugene facility for $6M
18 Apr 2024 //
ENDPTS
Vedanta Bio to Host Investor Meetings at the Leerink Partners 2024 Conference
06 Mar 2024 //
BUSINESSWIRE
Vedanta’s Key Microbiome Patents Fully Upheld in European Opposition Proceedings
28 Nov 2023 //
BUSINESSWIRE
Vedanta to Host Investor Meetings at Private Biotech Symposium
25 Oct 2023 //
BUSINESSWIRE
Vedanta Presents Progress from Two Defined Bacterial Consortia, VE303
11 Oct 2023 //
BUSINESSWIRE
Vedanta Biosciences to Participate at Upcoming Investor Conferences
05 Oct 2023 //
BUSINESSWIRE
Vedanta Biosciences Announces First Patient Dosed in Phase 2 Trial of VE202
04 Oct 2023 //
BUSINESSWIRE
Vedanta Bio Announces First Patient Dosed in Phase 2 Clinical Trial of VE202
04 Oct 2023 //
BUSINESSWIRE
Vedanta Bioscienceso Participate in the JMP Securities Life Sciences Conference
09 May 2023 //
BUSINESSWIRE
Vedanta Biosciences Receives Fast Track Designation for VE303
08 May 2023 //
BUSINESSWIRE
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline
25 Apr 2023 //
BUSINESSWIRE
Vedanta Biosciences Publishes Phase 2 Results in the Journal at ECCMID
17 Apr 2023 //
BUSINESSWIRE
Vedanta Biosciences to Present at Upcoming Investor Conferences
26 Jan 2023 //
BUSINESSWIRE
Vedanta to Present at the 9th International Human Microbiome Consortium Congress
09 Nov 2022 //
BUSINESSWIRE
Vedanta Biosciences to Present at Upcoming Investor Conferences
07 Jul 2022 //
BUSINESSWIRE
Vedanta opens manufacturing facility for lead candidate in PIII
30 Jun 2022 //
ENDPTS
Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility
28 Jun 2022 //
BUSINESSWIRE
PureTech`s Vedanta Biosciences Presents Data from Multiple Studies at DDW
23 May 2022 //
BUSINESSWIRE
Vedanta Biosciences Publishes Phase 1a/1b Results for VE303
13 Apr 2022 //
BUSINESSWIRE
Vedanta Biosciences to Present at Chardan’s 2022 Medicines Summit
23 Feb 2022 //
BUSINESSWIRE
Vedanta wins lead microbiome program, clears PhII test & nabs BARDA investment
06 Oct 2021 //
ENDPTS
Vedanta makes Clostridioides difficile look easy
05 Oct 2021 //
EVALUATE
Vedanta raises $68M, reveals setback to Bristol Myers alliance
21 Jul 2021 //
FIERCEBIOTECH
Vedanta Biosciences announces phase 1 study of VE202 for treatment of IBD
02 Jul 2021 //
PHARMABIZ
Vedanta Biosciences Announces New Data from Phase 1 Study of VE202
30 Jun 2021 //
BUSINESSWIRE
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202
29 Jun 2021 //
BUSINESSWIRE
Vedanta’s first Covid vaccination held at its Jharsuguda aluminium plant
21 Jan 2021 //
PHARMABIZ
Vedanta’s first Covid vaccination held at its Jharsuguda aluminium plant
20 Jan 2021 //
PHARMABIZ
Pfizer`s investment fund is making waves in VC — including a $25M
14 Jan 2021 //
ENDPTS
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
12 Jan 2021 //
BUSINESSWIRE
Pfizer invests $25m in Vedanta BioSciences` IBD treatment
12 Jan 2021 //
PHARMAFILE
PureTech Founded Entity Vedanta Biosciences Announces $25 M
11 Jan 2021 //
BUSINESSWIRE
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc.
11 Jan 2021 //
BUSINESSWIRE
Vedanta Announces Additional Pharmacokinetics Data From Ph1 Study of VE202
12 Oct 2020 //
BUSINESSWIRE
PureTech Founded Entity Vedanta Biosciences Additional Pharmacokinetics Data
12 Oct 2020 //
PRESS RELEASE
BARDA boosts the fight against antibiotic-resistant infections with $144M awards
01 Oct 2020 //
ENDPTS
Vedanta Biosciences Awarded Up to $76.9M Including $7.4 M Upfront from BARDA
30 Sep 2020 //
BUSINESSWIRE
Vedanta Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA t
29 Sep 2020 //
BUSINESSWIRE
Vedanta Biosciences taps Big Pharma vet Jeffrey Silber as CMO
18 Sep 2020 //
ENDPTS
Vedanta Resources raises $1.4 billion via bonds to support delisting
19 Aug 2020 //
MONEYCONTROL
Vedanta Biosciences Announces +VE Topline Data from Two Ph1 Studies of VE202
09 Jun 2020 //
BUSINESSWIRE
Vedanta Biosciences Announces Positive Topline Data from Two Ph1 Studies VE202
08 Jun 2020 //
BUSINESSWIRE
PureTech Affiliate Vedanta Biosciences Raises Additional $16.6 Million
24 Sep 2019 //
BIOSPACE
Microbiome upstart Vedanta gets an extra $18.5M in $45.5 Series C round
13 May 2019 //
ENDPTS
Vedanta Biosciences Initiates Phase 2 Study for VE303
27 Dec 2018 //
BIOSPECTRUM
